CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cellino and Matricelf (TASE: MTLF) announced today a collaboration to accelerate the global biomanufacturing of personalized spinal cord injury treatments using ...
NESS ZIONA, Israel, March 3, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a biotechnology company developing autologous engineered tissue therapies, today announced that it has signed a ...
TEL AVIV, Israel, March 24, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing autologous engineered neural tissue therapies, today announced a strategic ...
TEL AVIV, Israel, Feb. 7, 2022 /PRNewswire/ -- Matricelf (TASE:MTLF) announced today that scientists from Sagol Center for Regenerative Biotechnology at Tel Aviv University have engineered 3D spinal ...
Matricelf Ltd. is a biotechnology company, which engages in research and development of a platform for autologous matrix and cell implants in the field of regenerative medicine and tissue engineering.
NESS ZIONA, Israel, March 4, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered neural tissue implants for the treatment of spinal ...
Matricelf Ltd. Annual stock financials by MarketWatch. View the latest MTRLF financial statements, income statements and financial ratios.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results